{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:22:44Z","timestamp":1774380164360,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA138292"],"award-info":[{"award-number":["P30CA138292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Melphalan is an alkylating agent used in both autologous (ASCT) and allogeneic stem cell transplantation. It is a substrate of L\u2010type amino acid transporter\u20101 (LAT\u20101) and LAT\u20102, which are involved in its tissue penetration and elimination. Gabapentin and pregabalin, common concomitant medications in patients with multiple myeloma undergoing ASCT, are also substrates of LAT transporters, raising concern for potential competitive inhibition of melphalan transport. We evaluated whether concurrent use of gabapentin or pregabalin in patients receiving high\u2010dose melphalan (\u2265140\u00a0mg\/m<jats:sup>2<\/jats:sup>) prior to ASCT impacted frequency and severity of melphalan\u2010related adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to determine if concurrent administration of gabapentin or pregabalin and melphalan increased melphalan toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single\u2010center, retrospective evaluation including patients \u226518\u00a0years of age who received high\u2010dose melphalan as part of a conditioning regimen at the Winship Cancer Institute of Emory University between August 1, 2010 and April 1, 2020 and were followed through their transplant admission. After identification and inclusion of patients who received melphalan in combination with gabapentin or pregabalin, patient matching based on age (\u00b15\u00a0years), sex, and melphalan dose (140\u00a0mg\/m<jats:sup>2<\/jats:sup> or 200\u00a0mg\/m<jats:sup>2<\/jats:sup>) was utilized to generate a comparable cohort of patients who received melphalan alone. The primary outcome was hospital length of stay (LOS); secondary outcomes included supportive care requirements between days +4 and day +14 and time to neutrophil and platelet\u201020 engraftment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 176 patients evaluated in each group, median hospital LOS was 16\u00a0days, median time to neutrophil engraftment was 14\u00a0days, and median time to platelet\u201020 engraftment was 16\u00a0days in both groups. In addition, there were no significant differences in supportive care requirements between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this study, use of gabapentin or pregabalin in combination with melphalan did not impact safety of the conditioning regimen in patients undergoing ASCT.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2667","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T20:42:50Z","timestamp":1644007370000},"page":"233-240","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of concurrent gabapentin or pregabalin with high\u2010dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant"],"prefix":"10.1002","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5063-2191","authenticated-orcid":false,"given":"Akhilesh","family":"Sivakumar","sequence":"first","affiliation":[{"name":"Department of Pharmacy Winship Cancer Institute of Emory University  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan B.","family":"Bryson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Kentucky Healthcare  Lexington Kentucky USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin H.","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Winship Cancer Institute of Emory University  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn T.","family":"Maples","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Winship Cancer Institute of Emory University  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subir","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Shared Resource Winship Cancer Institute of Emory University  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha S.","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Emory University School of Medicine  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Emory University School of Medicine  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Emory University School of Medicine  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Emory University School of Medicine  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Emory University School of Medicine  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Donald","family":"Harvey","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Emory University School of Medicine  Atlanta Georgia USA"},{"name":"Department of Pharmacology and Chemical Biology Emory University School of Medicine  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"6","article-title":"Cytotoxic alpha amino acids and peptides","volume":"31","author":"Bergel F","year":"1953","journal-title":"Br Emp Cancer Campaign A"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.08.011"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1476\u20105586(04)80054\u2010x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20010027"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.49.34948"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.0086"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.346"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.03.022"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010018\u20102532\u20100"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751\u20105823.2011.00159_4.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010021\u201006385\u20105"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4636.4636"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705471"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756\u20106614\u20104\u2010S1\u2010S7"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2667","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2667","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:24:52Z","timestamp":1761056692000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1002\/phar.2667"],"URL":"https:\/\/doi.org\/10.1002\/phar.2667","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"2021-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}